Abbott Reports Double-Digit Sales and Ongoing Earnings Development in Fourth Quarter Abbott announced financial results for the fourth quarter ended Dec. 31, 2010 viagra online . Worldwide sales increased 13.4 % to nearly $10 billion, including an unfavorable 0.4 % effect of foreign exchange rates. Growth in the one fourth was driven by worldwide pharmaceutical product sales, which increased 22.5 %, like the contribution from the Solvay and Piramal acquisitions, as well as worldwide vascular products sales, which increased 13.7 %. Diluted earnings per share, excluding specified products, were $1.30, reflecting 10.2 % growth. Diluted earnings per share under Generally Accepted Accounting Principles were $0.92, primarily reflecting costs associated with recently announced restructuring actions for the integration of the Solvay Pharmaceuticals acquisition and in process R&D linked to the Reata collaboration.